(Reuters) - Gold prices were little changed on Tuesday, as concerns over spiking U.S. coronavirus cases offset pressure from vaccine optimism brought about by a positive vaccine trial data.
* Bullion dropped as much as 1.3% on Monday after drugmaker Moderna
* President-elect Joe Biden on Monday called on Congress to come together and pass a new coronavirus relief package.
* Forty U.S. states have reported record increases in COVID-19 cases in November, while 20 have seen a record rise in deaths and 26 reported record hospitalizations, according to a Reuters tally of public health data.
* Successful tests of two coronavirus vaccine candidates have increased the chance of a faster than expected U.S. economic recovery, Federal Reserve Vice Chair Richard Clarida said on Monday.
* The euro zone is facing a drawn-out recovery from a deep recession and needs more support from both the European Central Bank and governments, several policymakers said on Monday.
* Asian stocks opened firmer after the S&P 500 and Dow Jones indexes hit record highs on news of another promising coronavirus vaccine. [MKTS/GLOB]
* Speculators cut their net long position by 10,995 contracts to 110,957 on COMEX gold in week to Nov. 10, he U.S. Commodity Futures Trading Commission (CFTC) said on Monday.
(Reporting by Eileen Soreng in Bengaluru; Editing by Rashmi Aich)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)